| Contraception |
1 |
0.95 |
| Breast Cancer |
0 |
0.82 |
| Estrogen |
0 |
0.71 |
| Hormonal Contraception |
0 |
0.33 |
| Progestin |
0 |
0.33 |
| Vagina |
0 |
0.3 |
| Pregnancy |
0 |
0.29 |
| Body Mass Index |
0 |
0.27 |
| Clinical Research |
0 |
0.21 |
| Transdermal |
0 |
0.15 |
| Food and Drug Administration (FDA) |
0 |
0.14 |
| Breast |
0 |
0.13 |
| Biliary Disease |
0 |
0.12 |
| Liver |
0 |
0.12 |
| Thromboembolism |
0 |
0.11 |
| Breastfeeding |
0 |
0.09 |
| Generics |
0 |
0.09 |
| Hemorrhage |
0 |
0.06 |
| Receptors |
0 |
0.06 |
| Steroids |
0 |
0.06 |
| Tissue |
0 |
0.06 |
| Venous Thromboembolism (VTE) |
0 |
0.05 |
| Adrenal Insufficiency |
0 |
0.03 |
| Adverse Effects |
0 |
0.03 |
| Amenorrhea |
0 |
0.03 |
| Antithrombotics |
0 |
0.03 |
| Biliary Tract |
0 |
0.03 |
| Bone |
0 |
0.03 |
| Canada |
0 |
0.03 |
| Cancer |
0 |
0.03 |
| Drug Delivery System |
0 |
0.03 |
| Drug Interaction |
0 |
0.03 |
| Electronic Health Record (EHR) and Healthcare Technology |
0 |
0.03 |
| Gallstone |
0 |
0.03 |
| Gland |
0 |
0.03 |
| Gluteal Region |
0 |
0.03 |
| Heart |
0 |
0.03 |
| Hyperkalemia |
0 |
0.03 |
| Impairment |
0 |
0.03 |
| Intrauterine Device |
0 |
0.03 |
| Lipids Management |
0 |
0.03 |
| Medical Innovations |
0 |
0.03 |
| Menstrual Disorder |
0 |
0.03 |
| Nonsteroidal Anti-Inflammatory Agents |
0 |
0.03 |
| Pain Management |
0 |
0.03 |
| Patient Safety |
0 |
0.03 |
| Pharmacokinetics |
0 |
0.03 |
| Postpartum |
0 |
0.03 |
| Renal Failure |
0 |
0.03 |
| Triglycerides |
0 |
0.03 |
| Trunk |
0 |
0.03 |